Conference - El Jadida, Morocco
As many as 90% of all cancer deaths can be attributed to metastatic disease.Cells from the primary tumor, after travel to regional or distant sites, cause failure of essential organs including the lungs, liver, brain and bone marrow. Significant advances in the field make this an exciting time for the study of metastasis. Genetic signatures in primary tumors as well as circulating tumor cells and oligonucleotide or protein biomarkers hold the promise of predicting cancer outcomes and allowing selection of optimal drug candidates. The isolation of circulating tumor cells has further improved our ability to analyze the tumor genotype. The ability to metastasize is influenced by the invasive potential of cells in the primary tumor and particularly by self-renewing tumor cells that have properties of cancer stem cells. New results highlight the plasticity of tumor cells. Genetic and epigenetic changes take place over time both in the primary site and in the secondary metastatic sites. Tumor cells can take on the properties of mesenchymal cells or epithelial cells and transition back and forth between these two states. Furthermore, cells that occupy metastatic sites and primary sites may be so different that they respond to completely different drugs. An important current goal is the identification of agents that selectively target the cells in established tumor metastases.
Organization: Fusion Conferences Ltd
Tue, Sep 23, 2014 - Fri, Sep 26, 2014
Mazagan Beach Resort
El Jadida, Morocco
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.